Situaciones clínicas y tratamiento del Cáncer de Pulmón EGFR mutado

43 / 49

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
Trial Design
Open label, randomised phase II
Primary endpoint:
• PFS
Secundary endpoint:
• Objective response
Disease control (complete or partial response, or disease stabilisation)
• Overall survival
153 patients